Literature DB >> 15032581

The three Es of cancer immunoediting.

Gavin P Dunn1, Lloyd J Old, Robert D Schreiber.   

Abstract

After a century of controversy, the notion that the immune system regulates cancer development is experiencing a new resurgence. An overwhelming amount of data from animal models--together with compelling data from human patients--indicate that a functional cancer immunosurveillance process indeed exists that acts as an extrinsic tumor suppressor. However, it has also become clear that the immune system can facilitate tumor progression, at least in part, by sculpting the immunogenic phenotype of tumors as they develop. The recognition that immunity plays a dual role in the complex interactions between tumors and the host prompted a refinement of the cancer immunosurveillance hypothesis into one termed "cancer immunoediting." In this review, we summarize the history of the cancer immunosurveillance controversy and discuss its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape.

Entities:  

Mesh:

Year:  2004        PMID: 15032581     DOI: 10.1146/annurev.immunol.22.012703.104803

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  865 in total

Review 1.  Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology.

Authors:  Nobuyoshi Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-10-06       Impact factor: 3.402

2.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

3.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

Review 4.  Epidemiologic perspective on immune-surveillance in cancer.

Authors:  Daniel W Cramer; Olivera J Finn
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

Review 5.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 6.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

7.  CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ.

Authors:  Frederick Allen; Iuliana D Bobanga; Peter Rauhe; Deborah Barkauskas; Nathan Teich; Caryn Tong; Jay Myers; Alex Y Huang
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 8.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

Review 9.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 10.  Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

Authors:  Darya Alizadeh; Nicolas Larmonier
Journal:  Cancer Res       Date:  2014-04-28       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.